Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18602895 | EARLY DETECTION OF CONDITIONS AND/OR EVENTS | March 2024 | March 2026 | Abandon | 24 | 1 | 0 | No | No |
| 18686979 | SELF-SERVICE STATION AND MEDICAL INFORMATION MANAGEMENT SYSTEM FOR SCREENING MEDICAL CONSULTATIONS | February 2024 | February 2026 | Abandon | 24 | 1 | 0 | No | No |
| 18374004 | Method for Evaluating Biomarkers in a Biological Sample | September 2023 | November 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18473405 | MEDICATION TARGET PERSON MANAGEMENT SYSTEM, MANAGEMENT METHOD, MANAGEMENT CONTROL APPARATUS AND PROGRAM STORAGE MEDIUM | September 2023 | January 2026 | Abandon | 27 | 1 | 0 | No | No |
| 18463685 | MACHINE LEARNING METHOD FOR ENHANCING CARE OF A PATIENT USING VIDEO AND AUDIO ANALYTICS | September 2023 | December 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18269013 | INFORMATION PROCESSING METHOD, INFORMATION PROCESSING APPARATUS, AND NONTRANSITORY COMPUTER-READABLE STORAGE MEDIUM | June 2023 | December 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18338828 | SYSTEMS AND METHODS FOR REGISTERING AND REPORTING IN A TESTING PROGRAM | June 2023 | August 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18316678 | Collaborative Medical Diagnosis and Treatment System and Method of Use | May 2023 | September 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18168802 | Information Processing Apparatus, Information Processing Method, and Program | February 2023 | January 2026 | Abandon | 35 | 2 | 0 | No | No |
| 18003900 | SYSTEM, METHOD AND COMPUTER PROGRAM FOR PROVIDING AN ASSESSMENT OF A MEDICAL RISK, METHOD FOR OBTAINING A MODEL FOR THE SYSTEM, METHOD FOR ASSESSING A MEDICAL RISK AND NUTRITIONAL SUPPLEMENTS | December 2022 | June 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18069991 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | December 2022 | December 2025 | Abandon | 36 | 2 | 0 | Yes | No |
| 18076448 | SYSTEM FOR PROVIDING DIGITAL THERAPEUTIC AGENT TO TREAT TEMPOROMANDIBULAR JOINT DISEASE OF PATIENT | December 2022 | October 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17964869 | MODIFIABLE PHARMACEUTICAL PROTOCOL FOR MIGRAINE TREATMENT AND ASSESSMENT OF DRUG EFFICACY THEREOF | October 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17956012 | SYSTEM AND METHOD FOR INTELLIGENT DIAGNOSIS | September 2022 | June 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17951484 | BIOLOGICAL FUNCTION ESTIMATION DEVICE AND BIOLOGICAL FUNCTION ESTIMATION METHOD | September 2022 | January 2026 | Allow | 40 | 3 | 0 | Yes | No |
| 17891625 | SYSTEMS AND METHODS FOR VISUALIZATION OF MEDICAL RECORDS | August 2022 | June 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17856058 | SYSTEM AND METHOD FOR REAL-TIME PREDICTION OF HOSPITAL DISCHARGE DISPOSITION AND DEFERRING CLINICAL SERVICES | July 2022 | September 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17757685 | HEARING ASSISTANCE DEVICE MODEL PREDICTION | June 2022 | May 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17779857 | Monitoring System, Monitoring Method, and Monitoring Program | May 2022 | May 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17752820 | DISEASE RISK PREDICTION METHOD AND SYSTEM BASED ON BIOLOGICAL AGE USING MEDICAL CHECK-UP CLINICAL DATA INDEPENDENT OF DYSLIPIDEMIA DATA | May 2022 | November 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17749819 | METHOD AND SYSTEM FOR ELECTRONIC MEDICAL RECORD CREATION AND MEDICAL BILLING | May 2022 | October 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17768970 | PATIENT CONDITION PREDICTION APPARATUS, PATIENT CONDITION PREDICTION METHOD, AND COMPUTER PROGRAM | April 2022 | December 2024 | Abandon | 32 | 1 | 0 | Yes | No |
| 17654806 | SYSTEMS AND METHODS FOR POOLED SAMPLE COLLECTION AND IMPLEMENTING TESTING PROGRAMS | March 2022 | December 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17691341 | SYSTEMS AND METHODS FOR VERIFYING PRESCRIPTIONS | March 2022 | January 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17641480 | CLINICAL DECISION SUPPORT SCHEDULING AND ALERTS | March 2022 | October 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17645618 | SYSTEM TO PROVIDE TIMELY PRESCRIPTION INFORMATION | December 2021 | March 2025 | Abandon | 39 | 2 | 0 | Yes | No |
| 17558288 | CLINICAL DATA CONNECTOR AND CLINICAL DOCUMENT COLLECTOR FOR INDIVIDUAL ACCESS | December 2021 | October 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17558336 | AI Platform System and Method | December 2021 | April 2025 | Abandon | 40 | 2 | 0 | Yes | No |
| 17558277 | AI Platform System and Method | December 2021 | March 2025 | Abandon | 39 | 2 | 0 | Yes | No |
| 17558319 | AI Platform System and Method | December 2021 | September 2025 | Abandon | 45 | 2 | 0 | Yes | No |
| 17555704 | CONTAINER VAULT SYSTEM | December 2021 | July 2024 | Abandon | 31 | 2 | 0 | Yes | No |
| 17618683 | METHOD AND SYSTEM FOR MANAGING MEDICAL PROCESSES | December 2021 | July 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17614485 | METHOD AND SYSTEM FOR PERSONALIZING AND STANDARDIZING CANNABIS, PSYCHEDELIC AND BIOACTIVE PRODUCTS | November 2021 | June 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17603818 | AUXILIARY METHOD FOR DIAGNOSIS OF LOWER URINARY TRACT SYMPTOMS | November 2021 | November 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17499220 | SYSTEM AND METHOD FOR PERSONALIZATION OF SLEEP RESTRICTION THERAPY | October 2021 | January 2026 | Abandon | 51 | 4 | 0 | No | Yes |
| 17481395 | SYSTEM AND METHOD FOR PROVIDING DISEASE EARLY WARNING | September 2021 | September 2024 | Abandon | 36 | 2 | 0 | Yes | No |
| 17476883 | METHODS AND APPARATUS FOR A TELECARE COMMUNICATION SYSTEM | September 2021 | March 2026 | Abandon | 54 | 5 | 0 | Yes | No |
| 17460024 | METHOD, APPARATUS FOR PREDICTING EPIDEMIC SITUATION, DEVICE, STORAGE MEDIUM AND PROGRAM PRODUCT | August 2021 | September 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17458103 | INTEGRATING MANAGEMENT OF MOVEMENT SESSIONS WITH ELECTRONIC RECORD SYSTEM REPORTING REQUIREMENTS | August 2021 | July 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17368850 | METHOD FOR CALCULATING HIGH RISK ROUTE OF ADMINISTRATION | July 2021 | May 2024 | Abandon | 35 | 2 | 0 | Yes | No |
| 17361717 | MACHINE LEARNING-BASED ADJUSTMENT OF EPIDEMIOLOGICAL MODEL PROJECTIONS WITH FLEXIBLE PREDICTION HORIZON | June 2021 | August 2024 | Abandon | 38 | 2 | 0 | Yes | No |
| 17358561 | PRESERVING DATA INTEGRITY IN TASKS ACROSS A COMPUTING SYSTEM | June 2021 | October 2025 | Abandon | 52 | 4 | 0 | Yes | No |
| 17340419 | METHODS AND SYSTEMS FOR LEVERAGING HEALTHCARE CLAIMS FOR A HEALTHCARE PROVIDER SEARCH | June 2021 | September 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17335371 | METHOD, APPARATUS, AND NON-TRANSITORY COMPUTER READABLE MEDIUM FOR MANAGING MEDICAL IMAGES | June 2021 | May 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17335157 | ELECTRONIC DEVICE, COMPUTER-READABLE NON-TRANSITORY RECORDING MEDIUM STORING PHARMACY RESERVATION PROGRAM, AND PHARMACY RESERVATION SYSTEM | June 2021 | January 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17243649 | MITIGATING OPEN SPACE HEALTH RISK FACTORS | April 2021 | February 2026 | Abandon | 57 | 6 | 0 | Yes | No |
| 17239893 | CONSUMPTION WEARABLE | April 2021 | March 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17239777 | SIDE EFFECT AND SYMPTOM RELIEF | April 2021 | January 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17231937 | System and Method for Obtaining Post-Infection Clearance | April 2021 | July 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17285230 | NURSING ASSISTANCE DEVICE, NURSING ASSISTANCE METHOD, AND RECORDING MEDIUM | April 2021 | April 2024 | Abandon | 36 | 1 | 0 | Yes | No |
| 17226001 | System and Method for Obtaining Clearance | April 2021 | June 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17217925 | System and Method for Audible Prescription Label Information Using RFID Prescription Packaging | March 2021 | July 2025 | Allow | 52 | 5 | 0 | Yes | Yes |
| 17213708 | SYSTEM AND METHODS FOR A CLOUD-BASED USER-INTERACTIVE PARTOGRAM | March 2021 | November 2025 | Abandon | 56 | 5 | 0 | Yes | No |
| 17278539 | SYSTEM AND METHOD TO IMPROVE INTERACTION BETWEEN USERS THROUGH MONITORING OF EMOTIONAL STATE OF THE USERS AND REINFORCEMENT OF GOAL STATES | March 2021 | March 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17205457 | COMPUTING DEVICE, METHOD AND COMPUTER PROGRAM PRODUCT FOR CONSTRUCTING A CONSOLIDATED MESSAGE | March 2021 | July 2025 | Allow | 52 | 4 | 0 | No | No |
| 17180301 | INFLUENCING END-STAGE RENAL DISEASE OUTCOMES THROUGH PREDICTING PHYSIOLOGICAL PARAMETERS AND DETERMINING DOSING RECOMMENDATIONS | February 2021 | November 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17173124 | METHOD, APPARATUS AND DEVICE FOR PROCESSING DISEASE INFORMATION, AND STORAGE MEDIUM | February 2021 | November 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17159030 | METHODS AND SYSTEMS FOR HEALTH MANAGEMENT | January 2021 | November 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17157554 | ELECTRONIC MEDICAL RECORD SYSTEM PROVIDING CROSS-PATIENT DATA POPULATION AND DISPLAY | January 2021 | October 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17145807 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND NON-TRANSITORY RECORDING MEDIUM ON WHICH PROGRAM FOR INFORMATION PROCESSING IS RECORDED | January 2021 | December 2024 | Abandon | 48 | 3 | 0 | Yes | No |
| 17125707 | SYSTEM FOR INTEGRATING DATA FOR CLINICAL DECISIONS INCLUDING MEDICINE DATA AND GENE DATA | December 2020 | April 2024 | Abandon | 40 | 3 | 0 | No | No |
| 17247427 | METHODS AND SYSTEMS FOR IMPROVING HEALTHCARE WORKFLOW | December 2020 | May 2025 | Abandon | 53 | 4 | 0 | Yes | No |
| 17110892 | PATIENT BED EXIT PREDICTION | December 2020 | December 2023 | Abandon | 37 | 2 | 0 | Yes | No |
| 17247114 | MEDICAL RECORD MANAGEMENT BASED ON HUB-AND-SPOKE SYSTEM | November 2020 | December 2024 | Abandon | 48 | 4 | 0 | Yes | No |
| 17100154 | DEVICE BASED RESPONDER NETWORK ACTIVATION AND VIRTUAL ASSISTANT INTEGRATION | November 2020 | July 2024 | Abandon | 44 | 4 | 0 | Yes | No |
| 17061086 | SINGLE CLICK APP CONTROLLED POINT-OF-CARE PHARMACY DRUG DISPENSING | October 2020 | August 2023 | Abandon | 35 | 1 | 0 | No | No |
| 15872274 | SYSTEM AND METHOD FOR AUTOMATED DIAGNOSIS AND TREATMENT | January 2018 | May 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAYNES, DAWN TRINAH.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HAYNES, DAWN TRINAH works in Art Unit 3686 and has examined 42 patent applications in our dataset. With an allowance rate of 4.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner HAYNES, DAWN TRINAH's allowance rate of 4.8% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAYNES, DAWN TRINAH receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAYNES, DAWN TRINAH is 38 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -0.5% benefit to allowance rate for applications examined by HAYNES, DAWN TRINAH. This interview benefit is in the 11% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 5.4% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 20% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.